| BTO | FXO | BTO / FXO | |
| Gain YTD | 17.015 | 9.374 | 182% |
| Net Assets | 825M | 1.1B | 75% |
| Total Expense Ratio | 2.01 | 0.60 | 335% |
| Turnover | 12.00 | 90.00 | 13% |
| Yield | 1.49 | 1.99 | 75% |
| Fund Existence | 32 years | 19 years | - |
| BTO | FXO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | N/A |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 87% |
| Momentum ODDS (%) | 1 day ago 87% | 1 day ago 75% |
| MACD ODDS (%) | N/A | 6 days ago 67% |
| TrendWeek ODDS (%) | 1 day ago 85% | 1 day ago 80% |
| TrendMonth ODDS (%) | 1 day ago 84% | 1 day ago 81% |
| Advances ODDS (%) | 11 days ago 90% | 1 day ago 85% |
| Declines ODDS (%) | 6 days ago 85% | 5 days ago 79% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 86% |
| Aroon ODDS (%) | 1 day ago 79% | 1 day ago 87% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| BIPIX | 93.22 | N/A | N/A |
| ProFunds Biotechnology UltraSector Inv | |||
| FKARX | 41.33 | N/A | N/A |
| Franklin Growth Opportunities R | |||
| CCWRX | 10.10 | N/A | N/A |
| Columbia Select Large Cap Growth Inst3 | |||
| RAFFX | 46.42 | -0.20 | -0.43% |
| American Funds AMCAP R-5 | |||
| IVIFX | 20.93 | -0.30 | -1.41% |
| Nomura International Core Equity C | |||
A.I.dvisor tells us that BTO and BAC have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BTO and BAC's prices will move in lockstep.
| Ticker / NAME | Correlation To BTO | 1D Price Change % | ||
|---|---|---|---|---|
| BTO | 100% | +0.41% | ||
| BAC - BTO | 24% Poorly correlated | -5.14% | ||
| USB - BTO | 23% Poorly correlated | -0.25% | ||
| FITB - BTO | 20% Poorly correlated | -0.62% | ||
| HBAN - BTO | 15% Poorly correlated | -0.53% | ||
| BPOP - BTO | 15% Poorly correlated | +1.20% | ||
More | ||||
A.I.dvisor indicates that over the last year, FXO has been closely correlated with ASB. These tickers have moved in lockstep 85% of the time. This A.I.-generated data suggests there is a high statistical probability that if FXO jumps, then ASB could also see price increases.